Compare NMIH & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | AGIO |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2013 | 2013 |
| Metric | NMIH | AGIO |
|---|---|---|
| Price | $44.16 | $34.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $43.25 | $38.88 |
| AVG Volume (30 Days) | 385.3K | ★ 914.1K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $706,440,000.00 | $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | $4.34 | $170.73 |
| P/E Ratio | $16.67 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $34.84 | $22.24 |
| 52 Week High | $46.74 | $46.00 |
| Indicator | NMIH | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 50.18 |
| Support Level | $43.55 | $32.54 |
| Resistance Level | $46.51 | $36.04 |
| Average True Range (ATR) | 0.69 | 1.17 |
| MACD | -0.28 | 0.15 |
| Stochastic Oscillator | 7.91 | 43.71 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.